CN112402508A - 一种治疗带状疱疹的中药组合物及其制备方法 - Google Patents
一种治疗带状疱疹的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN112402508A CN112402508A CN202011470153.4A CN202011470153A CN112402508A CN 112402508 A CN112402508 A CN 112402508A CN 202011470153 A CN202011470153 A CN 202011470153A CN 112402508 A CN112402508 A CN 112402508A
- Authority
- CN
- China
- Prior art keywords
- parts
- myrrh
- frankincense
- herpes zoster
- realgar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 208000007514 Herpes zoster Diseases 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000004863 Frankincense Substances 0.000 claims abstract description 64
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 52
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 52
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 50
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 49
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 49
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 45
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 45
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 43
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 43
- 229910052957 realgar Inorganic materials 0.000 claims abstract description 41
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 34
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 33
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940116229 borneol Drugs 0.000 claims abstract description 33
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims abstract description 32
- 244000107975 Strychnos nux-vomica Species 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 241000218691 Cupressaceae Species 0.000 claims abstract description 19
- 240000004980 Rheum officinale Species 0.000 claims abstract description 18
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 241000972673 Phellodendron amurense Species 0.000 claims description 31
- 241000717739 Boswellia sacra Species 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 238000009835 boiling Methods 0.000 claims description 19
- 210000000582 semen Anatomy 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 241001057584 Myrrha Species 0.000 claims description 13
- 238000002791 soaking Methods 0.000 claims description 11
- 241000218202 Coptis Species 0.000 claims description 7
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 2
- 240000007551 Boswellia serrata Species 0.000 abstract description 42
- 208000002193 Pain Diseases 0.000 abstract description 38
- 230000036407 pain Effects 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 31
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 208000004296 neuralgia Diseases 0.000 abstract description 13
- 231100000331 toxic Toxicity 0.000 abstract description 12
- 230000002588 toxic effect Effects 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000005469 granulation Methods 0.000 abstract description 5
- 230000003179 granulation Effects 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 231100000241 scar Toxicity 0.000 abstract description 4
- 208000032544 Cicatrix Diseases 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 230000037387 scars Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000001338 necrotic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000009982 effect on human Effects 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 17
- 206010042674 Swelling Diseases 0.000 description 16
- 230000008961 swelling Effects 0.000 description 16
- 208000010201 Exanthema Diseases 0.000 description 13
- 201000005884 exanthem Diseases 0.000 description 13
- -1 methyl coptisine Chemical compound 0.000 description 13
- 206010037844 rash Diseases 0.000 description 13
- 239000000341 volatile oil Substances 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 241000219061 Rheum Species 0.000 description 11
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 11
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 206010007247 Carbuncle Diseases 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000010926 purge Methods 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000207929 Scutellaria Species 0.000 description 7
- 208000025865 Ulcer Diseases 0.000 description 7
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 7
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000011514 reflex Effects 0.000 description 7
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 6
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 6
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 5
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 201000000736 Amenorrhea Diseases 0.000 description 4
- 206010001928 Amenorrhoea Diseases 0.000 description 4
- 240000000572 Blumea balsamifera Species 0.000 description 4
- 206010010071 Coma Diseases 0.000 description 4
- 206010017553 Furuncle Diseases 0.000 description 4
- 241000972672 Phellodendron Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 231100000540 amenorrhea Toxicity 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 4
- 229940036350 bisabolol Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 239000010282 Emodin Substances 0.000 description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 3
- 208000003098 Ganglion Cysts Diseases 0.000 description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 3
- 208000005400 Synovial Cyst Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001543 purgative effect Effects 0.000 description 3
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- HHHQMKWPZAYIAE-WAIXHZNCSA-N (4ar,5as,6r,8as,13as,15as,15br)-10,11-dimethoxy-6-oxido-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-6-ium-14-one Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2C[N@@+]2([O-])[C@@H]3[C@]41CC2 HHHQMKWPZAYIAE-WAIXHZNCSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 2
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 2
- GYFSYEVKFOOLFZ-UHFFFAOYSA-N Berberrubine Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GYFSYEVKFOOLFZ-UHFFFAOYSA-N 0.000 description 2
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 2
- 241000208229 Burseraceae Species 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- MAYJEFRPIKEYBL-OASIGRBWSA-N Obacunone Chemical compound C=1([C@@H]2OC(=O)[C@H]3O[C@@]43[C@]3(C)C(=O)C[C@H]5C(C)(C)OC(=O)C=C[C@]5(C)[C@H]3CC[C@]42C)C=COC=1 MAYJEFRPIKEYBL-OASIGRBWSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241001279009 Strychnos toxifera Species 0.000 description 2
- 241000779819 Syncarpia glomulifera Species 0.000 description 2
- 241001480046 Trichophyton schoenleinii Species 0.000 description 2
- 241001480050 Trichophyton violaceum Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 2
- 229940015301 baicalein Drugs 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GLYPKDKODVRYGP-UHFFFAOYSA-O berberrubine Natural products C1=C2CC[N+]3=CC4=C(O)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 GLYPKDKODVRYGP-UHFFFAOYSA-O 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- GLYPKDKODVRYGP-UHFFFAOYSA-N burberrubine Natural products C12=CC=3OCOC=3C=C2CCN2C1=CC1=CC=C(OC)C(=O)C1=C2 GLYPKDKODVRYGP-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 210000000613 ear canal Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- VSLDMVSILHVDSR-UHFFFAOYSA-N obacunone Natural products CC1(C)OC(=O)C=CC2(C)C1CC(=O)C3(C)C2CCC4(C)C(OC(=O)C5OC345)c6occc6 VSLDMVSILHVDSR-UHFFFAOYSA-N 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008601 oleoresin Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000001739 pinus spp. Substances 0.000 description 2
- JNNROFOMHXIAMQ-UDSSAEOASA-N pseudobrucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@]3(O)[C@]41CC2 JNNROFOMHXIAMQ-UDSSAEOASA-N 0.000 description 2
- HCCFPODVEOBUMM-YOQTYQRRSA-N pseudostrychnine Chemical compound O([C@H]1CC2=O)CC=C3CN4CC[C@@]56C7=CC=CC=C7N2[C@H]6[C@H]1[C@H]3C[C@@]54O HCCFPODVEOBUMM-YOQTYQRRSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005453 strychnine Drugs 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229940036248 turpentine Drugs 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-LSDHHAIUSA-N β-bisabolol Chemical compound CC(C)=CCC[C@H](C)[C@]1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-LSDHHAIUSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- LFJQCDVYDGGFCH-JTQLQIEISA-N (+)-β-phellandrene Chemical compound CC(C)[C@@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-JTQLQIEISA-N 0.000 description 1
- LFJQCDVYDGGFCH-SNVBAGLBSA-N (+/-)-beta-Phellandrene Natural products CC(C)[C@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-SNVBAGLBSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- FAUPZRZWQZAAOB-SUJBTXFYSA-N (4ar,5as,8ar,13as,15as,15br)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2h-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinoline-14-one;nitric acid Chemical compound O[N+]([O-])=O.O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 FAUPZRZWQZAAOB-SUJBTXFYSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- GDVRUDXLQBVIKP-HQHREHCSSA-N 1-O-galloyl-beta-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(=O)C1=CC(O)=C(O)C(O)=C1 GDVRUDXLQBVIKP-HQHREHCSSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 description 1
- CQSRUKJFZKVYCY-OYLIUYJJSA-N 5alpha-24E-ethylidene-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1C2[C@@H]2CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]2(C)CC1 CQSRUKJFZKVYCY-OYLIUYJJSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001252601 Blumea Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000018062 Boswellia Nutrition 0.000 description 1
- 206010055000 Bromhidrosis Diseases 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000754688 Cercaria Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000037803 Coptis deltoidea Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- QXKAIJAYHKCRRA-JJYYJPOSSA-N D-arabinonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(O)=O QXKAIJAYHKCRRA-JJYYJPOSSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- AQASRZOCERRGBL-UHFFFAOYSA-N Dauricine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C1CC1=CC=C(O)C(OC2=CC=C(C=C2)CC2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 229920000296 Glucogallin Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241001113846 Loganiaceae Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 206010033081 Otitis media chronic Diseases 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- RUOKEYJFAJITAG-UHFFFAOYSA-N Resveratroloside Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1)=CC=C1C=CC1=CC(O)=CC(O)=C1 RUOKEYJFAJITAG-UHFFFAOYSA-N 0.000 description 1
- OZFQHULMMDWMIV-UHFFFAOYSA-N Rheinanthrone Chemical compound C1=CC=C2CC3=CC(C(=O)O)=CC(O)=C3C(=O)C2=C1O OZFQHULMMDWMIV-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- YSKVBPGQYRAUQO-UHFFFAOYSA-N Schottenol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 YSKVBPGQYRAUQO-UHFFFAOYSA-N 0.000 description 1
- 101000874322 Scutellaria baicalensis Baicalin-beta-D-glucuronidase Proteins 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 244000299492 Thespesia populnea Species 0.000 description 1
- 235000009430 Thespesia populnea Nutrition 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241000196252 Ulva Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LNOHXHDWGCMVCO-UHFFFAOYSA-N Wogonoside Natural products C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1OC1OC(C(O)=O)C(O)C(O)C1O LNOHXHDWGCMVCO-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000002952 aconitine derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- BZXULBWGROURAF-UHFFFAOYSA-N alpha-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C BZXULBWGROURAF-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000003836 berberines Chemical group 0.000 description 1
- 229940074775 beta-bisabolol Drugs 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- LFJQCDVYDGGFCH-UHFFFAOYSA-N beta-phellandrene Natural products CC(C)C1CCC(=C)C=C1 LFJQCDVYDGGFCH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 159000000007 calcium salts Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229940117948 caryophyllene Drugs 0.000 description 1
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010354 chronic purulent otitis media Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- GJWSUKYXUMVMGX-UHFFFAOYSA-N citronellic acid Chemical compound OC(=O)CC(C)CCC=C(C)C GJWSUKYXUMVMGX-UHFFFAOYSA-N 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- AQASRZOCERRGBL-ROJLCIKYSA-N dauricine Chemical compound CN1CCC2=CC(OC)=C(OC)C=C2[C@H]1CC1=CC=C(O)C(OC2=CC=C(C=C2)C[C@H]2N(C)CCC=3C=C(C(=CC=32)OC)OC)=C1 AQASRZOCERRGBL-ROJLCIKYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 201000010582 ecthyma Diseases 0.000 description 1
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- WAFDWKYNSTVECG-UHFFFAOYSA-L magnesium;3-[(4-nitrophenyl)methoxy]-3-oxopropanoate Chemical compound [Mg+2].[O-]C(=O)CC(=O)OCC1=CC=C([N+]([O-])=O)C=C1.[O-]C(=O)CC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 WAFDWKYNSTVECG-UHFFFAOYSA-L 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000008653 root damage Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- JNNROFOMHXIAMQ-UHFFFAOYSA-N sec-pseudobrucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5(O)C31CC2 JNNROFOMHXIAMQ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-CXZNLNCXSA-N sennoside A Natural products O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)cccc34)c2c1 IPQVTOJGNYVQEO-CXZNLNCXSA-N 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- ADTDBAKUQAKBGZ-VXJIXCKJSA-N strychnine N-oxide Chemical compound O([C@H]1CC(=O)N(C=2C3=CC=CC=2)[C@H]2[C@H]1[C@H]1C4)CC=C1C[N+]1([O-])[C@@H]4[C@]23CC1 ADTDBAKUQAKBGZ-VXJIXCKJSA-N 0.000 description 1
- 229910052569 sulfide mineral Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229920006029 tetra-polymer Polymers 0.000 description 1
- XPDICGYEJXYUDW-UHFFFAOYSA-N tetraarsenic tetrasulfide Chemical compound S1[As]2S[As]3[As]1S[As]2S3 XPDICGYEJXYUDW-UHFFFAOYSA-N 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- LNOHXHDWGCMVCO-NTKSAMNMSA-N wogonin 7-O-beta-D-glucuronide Chemical compound C1=C(O)C(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C(OC)=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LNOHXHDWGCMVCO-NTKSAMNMSA-N 0.000 description 1
- 229930000053 β-bisabolol Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种用于治疗带状疱疹的中药组合物及其制备方法,该带状疱疹组合物由如下原料制成:黄连、黄芩、黄柏、大黄、马钱子、冰片、乳香、没药、雄黄,针对带状疱疹形成的病因和病机,利用多种中药的活性成分的相互协同作用,通过清热解毒,燥湿化瘀、止痛、去腐生肌,治疗带状疱疹,而且不留疤痕和神经痛等后遗症,对其他治疗后具有神经痛后遗症的治疗效果好。本发明制备的带状疱疹组合物,可以被制备成任何一种常用的外用制剂,对带状疱疹的疗效显著,总有效率达到100%,本发明组合物治疗带状疱疹疗程短、费用低、疗效高对人体无副作用。
Description
技术领域
本发明涉及一种中成药及其制备方法,特别涉及一种治疗带状疱疹的中药组合物及其制备方法。
背景技术
带状疱疹是由水痘一带状疱疹病毒感染引起的急性感染性皮肤病。对此病毒无免疫力的儿童被感染后,发生水痘。部分患者被感染后成为带病毒者而不发生症状。由于病毒具有亲神经性,感染后可长期潜伏于脊髓神经后根神经节的神经元内,当抵抗力低下或劳累、感染、感冒时,病毒可再次生长繁殖,并沿神经纤维移至皮肤,使受侵犯的神经和皮肤产生强烈的炎症。皮疹一般有单侧性和按神经节段分布的特点,有集簇性的疱疹组成,并伴有疼痛;年龄愈大,神经痛愈重。本病好发于成人,春秋季节多见。发病率随年龄增大而呈显著上升。
人是水痘-带状疱疹病毒的惟一宿主,病毒经呼吸道黏膜进入血液形成病毒血症,发生水痘或呈隐性感染,以后病毒可长期潜伏在脊髓后根神经节或者颅神经感觉神经节内。当机体受到某种刺激(如创伤、疲劳、恶性肿瘤或病后虚弱等)导致机体抵抗力下降时,潜伏病毒被激活,沿感觉神经轴索下行到达该神经所支配区域的皮肤内复制产生水疱,同时受累神经发生炎症、坏死,产生神经痛。
带状疱疹好发部位依次为肋间神经、颈神经、三叉神经和腰骶神经支配区域,表现为簇集成群的密集性小水疱,沿一侧周围神经作带状分布,有明显的神经痛,伴有局部淋巴结肿大。带状疱疹可发生于任何年龄、发生于身体的躯干四肢的任何部位,表现局部肌肤红肿、皮疹、小水疱、糜烂、浅溃疡。患处神经痛和局部淋巴结肿痛,以神经痛最为突出,约占92%以上,痛疼难以忍受。患处常首先出现潮红斑,很快出现粟粒至黄豆大小的丘疹,簇状分布而不融合,继之迅速变为水疱,疱壁紧张发亮,疱液澄清,外周绕以红晕,各簇水疱群间皮肤正常;皮损沿某一周围神经呈带状排列,多发生在身体的一侧,一般不超过正中线。神经痛为本病特征之一,可在发病前或伴随皮损出现,老年患者常较为剧烈。水疱干涸、结痂脱落后留有暂时性淡红斑或色素沉着,而且老年患者容易留有神经痛的后遗症。
带状疱疹中医谓之缠腰火丹、串腰龙,是由湿热内蕴、外感毒邪、湿热毒邪搏结、气血不通、壅滞肌肤所致,分为轻、中、重三型。轻型:疱起才一、二日皮肤潮红、水疱大如粟粒,灼痛刺痛,舌质红、脉、弦;中型:病已三、四日,皮肤焮红,族状水疱,晶莹、肿胀、灼痛刺痛较剧,舌质红、脉弦数;重型:疱已五至七日或更久,色赤或紫或有脓痂,灼痛刺痛难忍、伴发热、心烦、纳呆、溲赤,舌质红、脉数据其临床现象。
中医认为带状疱疹是由湿热内蕴、外感毒邪、湿热毒邪搏结、气血不通、壅滞肌肤所致。对带状疱疹的治疗,中医目前采用(1)内服法:用龙胆泻肝丸、苦胆草片、牛黄解毒片、板蓝根/大青叶煎汤代茶饮、板蓝根冲剂;(2)外治法:水疱未破者,选用雄冰酒、雄倍散、石灰酒或以桑螵蛸研末后加麻油调匀涂抹患处;水疱疹红赤则外涂玉露膏;水疱溃破糜烂者则外敷金黄膏;若有坏死,脓腐未脱者用九一丹掺在黄连膏上贴敷;西医主要采用药物治疗、神经阻滞、神经毁损、疫苗4种治疗方法,其中:(1)药物疗法主要采用抗病毒药物如阿昔洛韦、伐昔洛韦或泛昔洛韦;神经痛药物治疗,例如抗抑郁药(帕罗西汀(塞乐特)、氟西汀(百优解)、氟伏草胺、舍曲林等);抗惊厥药(卡马西平、丙戊酸钠等);麻醉性镇痛药(以吗啡为代表的镇痛药物,如吗啡(美施康定)、羟基吗啡酮(奥施康定)、羟考酮、芬太尼(多瑞吉)、二氢埃托菲、路盖克等);非麻醉性镇痛药(NSAIDs、曲吗多、乌头生物碱、辣椒碱等);(2)重度疼痛至药物难以控制时,考虑用直接有效的感觉神经阻滞疗法,阻滞定位的选择应取决于病变范围及治疗反应。总的原则应当是从浅到深,从简单到复杂,从末梢到神经干、神经根;(3)神经毁损是治疗最为直接有效的方法,神经毁损治疗还包括内侧丘脑立体定向放射治疗(伽玛刀或X刀),手术硬脊膜下腔脊髓背根毁损治疗、垂体毁损、交感干神经节毁损等;(4)接种疫苗,2020年7月起首次在北京、上海两地50岁以上人群可以接种带状疮疹疫苗了(欣安立适shingrix商品名)。但问题在于不是大部份人更不是每个人一生中都会患带状疤疹。据現在流行病学显示,大概每年1000人中仅有3至5个发生带状疮疹,问题是1000中哪3至5个人会患是无法预先可判定的事,总不能全民都来接种带状疱疹疫苗吧,那样的話国家每年要花费多少外汇,又要动用多少人力资源,况且接种疫苗后的有效期只有4年,也就是说每4年要接种一次,而且有效率只有95%,还有不良反应和禁忌人员禁忌症。
带状疱疹采用西医医疗过程中,儿童及年青人约2至3周痊愈,老年人约3至4周或更久治愈。但是老年患者,易有后遗症,所谓后遗症,就是患处肌肤表面上与正常肌肤一样,但是患者还是神经痛,其痛疼程度和频率与原先患带状疱疹时几乎一样,必须要住院手术割断此神经。有些后遗症患者因手术医生的技术缘故,动几次事术后,还是原样神经痛。
发明内容
本发明的首要目的是针对上述问题提供一种用于治疗带状疱疹的中药组合物及其制备方法,该组合物针对带状疱疹形成的病因和病机,利用多种中药的活性成分的相互协同作用,通过清热解毒,燥湿、化瘀止痛、去腐生肌,治疗带状疱疹,不仅疗效迅速,而且不留疤痕和神经痛等后遗症。
为实现本发明的目的,本发明一方面提供一种治疗带状疱疹的中药组合物,包括如下原料制成:黄连、黄芩、黄柏、大黄、马钱子粉、冰片、乳香、没药、雄黄、医用酒精。
其中,治疗带状疱疹的组合物原料的重量份配比为:黄连5-40、黄芩10-50、黄柏4-40、大黄7-30、马钱子粉10-25、冰片4-30、乳香12-35、没药5-40、雄黄25-55,医用酒精适量。
特别是,所述原料的重量份配比优选为:黄连10-30、黄芩10-25、黄柏10-35、大黄15-25、马钱子粉10-20、冰片10-25、乳香15-20、没药10-30、雄黄30-40,医用酒精适量。
尤其是,所述原料的重量份配比优选为:黄连20、黄芩20、黄柏20、大黄20、马钱子粉20、冰片20、乳香20、没药20、雄黄40,医用酒精适量。
特别是,所述医用酒精选择浓度为75%(v/v)的医用酒精。
尤其是,所述乳香选择制乳香;所述没药选择制没药;所述马钱子选择粒度小于100目的马钱子粉(即过100目筛后的细粉);所述雄黄选择粒度为小于100目的雄黄粉(即过100目筛后的细粉)。
其中,黄连又称云连、雅连、川连、味连、鸡爪连,为毛茛科植物黄连、三角叶黄连或云连的干燥根茎。性寒味苦,归心、脾、胃、肝、胆、大肠经。具有清热燥湿,泻火解毒。用于治疗热病邪入心经之高热;烦躁;谵妄或热盛迫血妄行之吐衄;湿热痞满,呕吐吞酸,泻痢,黄疸,高热神昏,心火亢盛,心烦不寐,血热吐衄,目赤,牙痛,消渴,痈肿疔疮;外治湿疹,湿疮,耳道流脓。酒黄连善清上焦火热。用于目赤,口疮。黄连中主要含有小檗碱、黄连碱、表小檗碱、小檗红碱、药根碱、木兰花碱、甲基黄连碱、掌叶防已碱、非洲防己碱等生物碱,还含黄柏酮、阿魏酸、黄柏内酯等成分。
现代药理研究表明黄连具有抗菌、抗真菌作用,抗病毒作用,抗炎和抗腹泻作用等。黄连煎剂50%浓度,鸡胚法实验表明对流感病毒PR8株、甲型流感病毒56-S8株、亚甲型病毒FMl株、乙型流感病毒Lee株、内型流感病毒1233株均有抑制作用;黄连煎剂25-100%浓度对乙型肝炎病毒DNA有抑制作用;黄连的有效成分小檗碱能有效地降低沙眼病毒感染鸡胚的死亡率,并抑制病毒原生小体的产生。临床上用黄连粉1份加蓖麻油3份调成混悬液,涂患部,治疗湿疹。
黄芩为唇形科植物黄芩的干燥根,以清火、养阴、败毒为主,气微,味苦,性寒,归肺、胆、脾、大肠、小肠经,具有清热燥湿,泻火解毒,止血,安胎的作用,主要用于治疗温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。
黄芩含有的化学成分主要是黄酮类化合物,主要有黄芩甙元、黄芩甙、汉黄芩素、汉黄芩甙、黄芩新素、木蝴蝶素A、黄芩黄酮等,还含有苯乙酮、棕榈酸、油酸、脯氨酸、苯甲酸、黄芩酶、β-谷甾醇、菜油甾醇及豆甾醇等。黄芩具有抗炎、抗病毒、抗变态反应、抗微生物的作用,降压、利尿作用,解热、解痉和镇静作用。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性;黄芩煎剂25-100%浓度,体外试验对乙型肝炎病毒DNA复制有抑制作用;黄芩70%乙醇提取物500mg/kg灌胃,对大鼠佐剂性关节炎有抑制作用;可抑制醋酸引起的小鼠腹腔渗出增加,对大鼠足肿也有抑制作用;黄芩煎剂4g/kg腹腔注射,对小鼠防御性条件反射可使阳性反射时延长,而对非条件反射及分化无影响,说明黄芩可加强皮层抑制过程。黄芩煎剂2g/kg,对伤寒混合疫苗致热家兔有解热作用。
黄柏为芸香科植物黄皮树或黄檗的干燥树皮,又称黄檗、元柏、檗木。黄柏性寒,味苦,归肾、膀胱经,具有清热燥湿,泻火除蒸,解毒疗疮之功效,用于治疗湿热泻痢,黄疸,带下,热淋,脚气,骨蒸劳热,盗汗,遗精,疮疡肿毒,湿疹瘙痒。盐黄柏滋阴降火。用于阴虚火旺,盗汗骨蒸。
黄柏含有如下化学成分:小檗碱、药根碱、木兰花碱、黄柏碱、小檗红碱、N-甲基大麦芽碱、掌叶防己碱、白栝楼碱、胍、蝙蝠葛碱等生物碱;另含黄柏酮、黄柏内酯、白鲜交酯、黄柏酮酸、青萤光酸、7-脱氢豆甾醇、豆甾醇、β-谷甾醇、菜油甾醇、黄柏甙、脱氢黄柏甙、脱氢异黄柏甙、白鲜交酯、24-亚甲基环木菠萝醇、牛奶树醇-B、异黄柏甙金丝桃甙和挥发油。
药理研究表明黄柏具有(1)抗菌作用,其抗菌有效成分为小檗碱。黄柏对金黄色葡萄球菌、肺炎球菌、白喉杆菌、草绿色链球菌、痢疾杆菌等均有效。(2)降压作用,降压作用显著而持久,因此降压可能是中枢性的。(3)镇咳作用,抗炎和抗溃疡的作用。(4)增强免疫功能的作用,黄柏煎剂,100%浓度,0.3ml/只灌胃,连续7天,能增加小鼠脾空斑形成细胞数。(5)抗病毒作用,黄柏煎剂6.25-100%浓度,体外试验,对乙型肝炎具有抑制作用,对慢性肝炎也有一定作用。(6)抗溃疡作用,黄柏提取物皮下注射或灌胃或皮内注射,对乙醇、阿斯匹林或幽门结扎诱发的大鼠胃溃疡有抑制作用。临床上黄柏用于治疗流行性脑脊髓膜炎、细菌性痢疾、肺炎、肺结核、肝硬化、慢性肝炎、极性结膜炎、慢性化脓性中耳炎等病疹;黄柏粉1份,香油1.2份,调成糊状,每日涂药1次,治疗耳部湿疹,涂药1~2次后85%以上患者湿烂面干燥结痂,5~7次后均基本好转或痊愈。
大黄别名将军、生军、川军,为蓼科植物掌叶大黄、唐古特大黄或药用大黄的干燥根及根茎。大黄性寒,味苦,归脾、胃、大肠、肝、心包经。具有泻热通肠,凉血解毒,逐瘀通经的功能,用于治疗实热便秘,积滞腹痛,泻痢不爽,湿热黄疸,血热吐衄,目赤,咽肿,肠痈腹痛,痈肿疔疮,瘀血经闭,跌打损伤。
大黄中的主要药效成分有蒽类衍生物,包括游离和结合状态的大黄酚、大黄酸、芦荟大黄素、大黄素、蜈蚣苔素、大黄素甲醚、大黄酚的单和双葡萄糖甙;大黄素、大黄素甲醚的单糖甙;还包括泻下成分:结合性大黄酸蒽酮-番泻甙A.B.C,其中番泻甙A为主要有效成分;另外还包括苷类化合物、鞣质类、有机酸类、挥发油类等,其中苷类化合物:土大黄甙、3,5,4’-三羟基芪烯一4’-O-β-D-(6’-O-没食子酰)葡萄糖甙、3,5,4’-三羟基茋烯-4’-O-β-D-吡喃葡萄糖甙等。鞣质类:没食子酰葡萄糖、d-儿茶素、没食子酸、大黄四聚素等。大黄四聚素经水解,得没食子酸、肉桂酸及大黄明。此外还含挥发油、植物甾醇、树脂和有机酸等。
大黄的药理研究表明大黄具有泻下和收敛作用,大黄中的番泻甙在肠道细菌酶的作用下分解产生大黄酸蒽酮,大黄酸蒽酮刺激大肠粘膜,使肠蠕动增加而泻下。大剂量使用大黄时先泻后便秘。若煎药时间过长,则蒽醌类化合物及结核性大黄酸和其类似物破坏较多,鞣酸等成分大量煎出,故仅有致便秘作用,而无泻下作用。大黄还可抑制肠细胞膜上Na+、K+—ATP酶,阻碍Na+转运,使肠内渗透压升高,保留大量水分,促进肠蠕动而泻下;有增加血小板、促进血液凝固等止血作用,其有效成分α-儿茶素、没食子酸可以促进血小板的粘附和聚集功能,增加血小板数和纤维蛋白原含量,降低抗凝血酶Ⅲ活性,使受伤局部的血管收缩,进而止血。抗感染、抑菌作用,大黄中的抗菌有效成分为大黄酸、大黄素、芦荟大黄素,大黄能抑制细菌核酸和蛋白质合成;抑制细菌生物氧化酶系统;诱生干扰素。大黄的抗菌作用强,抗菌谱广,其有效成分已证明为蒽醌衍生物,其中以大黄酸、大黄素和芦荟大黄素的抗菌作用最好。对痢疾杆菌、伤寒杆菌、霍乱弧菌、大肠杆菌、绿脓杆菌、葡萄球菌、链球菌、肺炎双球菌、白喉杆菌、炭疽杆菌及皮肤真菌等均有抗菌作用。
马钱子为马钱科植物马钱Strychnos nuxvomica L.的干燥成熟种子,味苦,性温,有大毒;归肝、脾经。马钱子具有通络止痛,散结消肿的功效,用于风湿顽痹,麻木瘫痪,跌扑损伤,痈疽肿痛;小儿麻痹后遗症,类风湿性关节痛。
马钱子的主要化学成分含生物碱分为3中类型,①“正”系列生物碱:番木鳖碱,马钱子碱,异番木鳖碱,异马钱子碱,番木鳖碱N-氧化物,马钱子碱N-氧化物,β-可鲁勃林,16-羟基-β-可鲁勃林,16-羟基-α-可鲁勃林;②“伪”系列生物碱:伪番木鳖碱,伪马钱子碱;③“N”-甲基伪”系列生物碱:N-甲基-断-伪番木鳖碱,番木鳖次碱,N-甲基-断-伪马钱子碱。种子经高温加热(220~260℃,3min),剧毒成分番木鳖碱、马钱子碱含量明显降低,而异番木鳖碱、异马钱子碱、番木鳖碱N-氧化物及马钱子碱N-氧化物含量增高。
马钱子的药理作用如下:对中枢神经系统的兴奋作用,首先兴奋脊髓的反射机能,其次兴奋延髓的呼吸中枢及血管运动中枢,并能提高大脑皮质的感觉中枢机能;脊髓对番木鳖碱有高度的敏感性,治疗剂量的番木鳖碱使神经冲动在脊髓中传导容易,并能提高脊髓反射兴奋性,因此可缩短脊髓反射时间,增高反射强度,且不破坏脊髓中枢的交互抑制过程,但中毒剂量的番木鳖碱能破坏此交互抑制过程。硝酸番木鳖碱治疗慢性再生障碍性贫血有效,马钱子分煎液促进体外培养的人淋巴细胞有丝分裂;马钱子含有的番本鳖碱具有强烈苦味,可刺激味觉感受器反射性增加胃液分泌,促进消化机能和食欲;马钱子的水煎剂对许兰氏黄癣菌,奥杜盎氏小芽胞癣菌有不同程度的抑制作用。体外试验表明,0.1%马钱子碱能完全抑制流感嗜血杆菌,肺炎双球菌,甲型链球菌和卡他球菌的生长。
马钱子粉为马钱子的炮制加工品,为黄褐色粉末,气糊香,味极苦,性温,有大毒,归肝、脾经。
冰片又称合成龙脑、梅片、艾粉、结片,为龙脑香科植物龙脑香树脂的加工品,或为樟脑、松节油等用化学方法合成的加工制成品,分为机制冰片、艾片两类。机制冰片以松节油、樟脑等为原料经化学方法合成的龙脑;艾片为菊科艾纳香属植物大风艾的鲜叶经蒸气蒸馏、冷却所得的结晶,又称“艾粉”或“结片”。冰片为无色透明或白色半透明的片状松脆结晶;气清香,味辛、凉;具挥发性,点燃发生浓烟,并有带光的火焰。本品在乙醇、氯仿或乙醚中易溶,在水中几乎不溶。冰片味辛、苦,性微寒;归心、脾、肺经。具有开窍醒神,清热止痛之功,用于热病神昏、痉厥,中风痰厥,气郁暴厥,中恶昏迷,目赤,口疮,咽喉肿痛,耳道流脓。
冰片的化学成分为从龙脑香的树脂和挥发油中取得的结晶,是近乎纯粹的右旋龙脑。龙脑香的树脂和挥发油中含有多种萜类成分。除龙脑外,尚含葎草烯、β-榄香烯、石竹烯等倍半萜,齐墩果酸、麦珠子酸、积雪草酸、龙脑香醇酮、龙脑香二醇酮、古柯二醇等三萜化合物。
冰片具有开窍醒神之功效,与麝香相须为用,治疗闭证神昏;与牛黄、麝番、黄连等配伍,用于治热病神昏、痰热内闭、暑热卒厥、小儿惊风等热闭;与温里祛寒及性偏温热的开窍药配伍,也可以治疗寒闭;还用于疮疡肿痛,溃后不敛,与血竭、乳香等同用,治疗疮疡溃后不敛;另外,冰片还用于治冠心病、心绞痛等。
冰片配伍黄柏:冰片苦辛性凉长于通诸窍、散郁火、去翳明目外用能清热消肿、止痒止痛;黄柏苦寒功擅清热燥湿、泻火解毒外用能燥湿敛疮。二者相伍外用有清热泻火、解毒消肿、燥湿敛疮、止痛止痒之功效用于治疗火热内郁上攻所引起的口腔糜烂、溃疡、口舌生疮、咽喉肿痛等症。
乳香为橄榄科植物卡氏乳香树的胶树脂,性温,味辛苦;归心、肝、脾经,具有活血行气;通经止痛;消肿生肌的功效,主要用于心腹疼痛;风湿痹痛;经闭痛经;跌打瘀痛;痈疽肿毒;肠痈;疮溃不敛的治疗。
乳香的化学成分含树脂60~70%,树胶27~35%,挥发油3~8%。树脂的主要成分为游离α、β-乳香脂酸,结合乳香脂酸,乳香树脂烃;树胶为阿糖酸的钙盐和镁盐,西黄芪胶粘素;此外,尚含苦味质;挥发油呈淡黄色,有芳香,含蒎烯,消旋-柠檬烯及α、β-水芹烯。
现代药理研究表明乳香具有镇痛作用,小鼠热板法证明乳香挥发油有镇痛作用,提取挥发油后的残渣无效;挥发油中的镇痛主要成为乙酸正辛酯;还具有消炎防腐的作用,乳香能促进多核白血球增加,以吞噬死亡的血球及细胞,改善新陈代谢,从而起消炎作用。
没药为橄榄科植物没药树或爱伦堡没药树的胶树脂,性平,味苦;入肝、脾、心、肾经。具有活血止痛;消肿生肌;散血去瘀的功效,主胸腹瘀痛;痛经;经闭;症瘕;跌打损伤;痈肿疮疡;肠痈;目赤肿痛;治跌损,金疮,筋骨,心腹诸痛,症瘕,经闭,痈疽肿痛,痔漏,目障。
没药中含有25~35%的树脂,2.5~9%的挥发油,57~65%的树胶,水分及各种杂质约3~4%。没药树脂大部分能溶于醚,不溶性部分含α及β罕没药酸,可溶性部分含α,β与γ没药酸、没药尼酸、α与β罕没药酚、罕没药树脂、没药萜醇;挥发油在空气中易树脂化,含丁香油酚、间苯甲酚、枯醛、藻烯、二戊烯、柠檬烯、桂皮醛、罕没药烯等;树胶水解得阿拉伯糖、半乳糖和木糖。
没药的水浸剂(1:2)在试管内对堇色毛癣菌、同心性毛癣菌、许兰氏黄癣菌等多种致病真菌有不同程度的抑制作用。没药的抗菌作用可能与含丁香曲酚有关。含油树脂部分能降低雄兔高胆甾醇血症(饲氢化植物油造成)的血胆甾醇含量,并能防止斑块形成,也能使家兔体重有所减轻。与其他含油树脂的物质相似,没药(一般用酊剂)有某些局部刺激作用,可用于口腔洗剂中,也可用于胃肠无力时以兴奋肠蠕动。水浸剂用试管稀释法,1:2对堇色毛癣菌等皮肤真菌有抑制作用。所含挥发油对霉菌有轻度抑制作用。没药煎剂20mg/kg股动脉注射,可使麻醉狗股动脉血流量增加,血管阻力下降。
乳香、没药,二药并用,为宣通脏腑、流通经络之要药,故凡心胃胁腹肢体关节诸疼痛皆能治之;外用为粉以敷疮疡,能解毒、消肿、生肌、止疼。乳香与没药二药并用不至耗伤气血,诚良药,最宜生用,若炒用之则其流通之力顿减。
雄黄,又称黄金石、石黄,为硫化物类矿物雄黄族雄黄,主含二硫化二砷(As2S2),性温,味苦,有毒;归肝、大肠经。雄黄具有解毒杀虫,燥湿祛痰,截疟的作用,主要用于痈肿疔疮,蛇虫咬伤,虫积腹痛,惊痫,疟疾,治疥癣,秃疮,痈疽,缠腰蛇丹,破伤风,蛇虫蟹伤,腋臭,臁疮,哮喘,喉痹,惊痫,痔瘘等。
雄黄的主要化学成分硫化砷AsS,并含少量其他重金属盐,其药理作用主要有(1)抗菌作用,雄黄水浸剂(1:2)在试管内对多种皮肤真菌有不同程度的抑制作用;对人型、牛型结核杆菌及耻垢杆菌有抑制生长的作用;用菖蒲、艾叶、雄黄合剂烟熏2~4小时以上,对金黄色葡萄球菌、变形杆菌、绿脓杆菌均有杀菌作用。(2)抗血吸虫作用,感染日本血吸虫尾蚴的小鼠,于感染前3天开始给雄黄、槟榔、阿魏、肉桂合剂0.2毫升/20克,感染后继续给药12天,成虫减少率达75.27%。
本发明另一方面提供一种治疗带状疱疹中药组合物的制备方法,包括如下步骤:
1)按照以下重量份配比备料:
黄连5-40、黄芩10-50、黄柏4-40、大黄7-30、马钱子粉10-25、冰片4-30、乳香12-35、没药5-40、雄黄25-55
2)将大黄、冰片、雄黄分别采用粉碎机进行粉碎,过100目筛,粉碎成粒度小于100目的大黄粉末、冰片粉末、雄黄粉末,备用;
3)向黄连、黄芩、黄柏、乳香、没药中加入水,进行浸泡处理;接着加热,煮沸,进行第一次煎煮处理;然后过滤,收集滤液;
4)向滤渣中加入水,加热、煮沸,再进行1-3次煎煮处理;并过滤,收集滤液;
5)合并滤液,并进行浓缩处理,获得浓缩煎煮液;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入医用酒精,搅拌均匀,即得。
其中,步骤1)中所述原料的重量份配比为:黄连10-30、黄芩10-25、黄柏10-35、大黄15-25、马钱子10-20、冰片10-25、乳香15-20、没药10-30、雄黄30-40。
特别是,所述原料的重量份配比优选为:黄连20、黄芩20、黄柏20、大黄20、马钱子粉20、冰片20、乳香20、没药20、雄黄40。
其中,步骤3)中所述原料黄连、黄芩、黄柏、乳香、没药的总质量之和与加入的水的体积之比为1:(5-10),优选为1:(6-9),进一步优选为1:6(m/v)。
特别是,步骤3)中所述浸泡处理时间至少30min,优选为30-60min;所述第一次煎煮处理温度为100℃;煎煮时间至少30min,优选为30-40min。
其中,步骤4)中所述加入的水体积与原料黄连、黄芩、黄柏、乳香、没药的总质量之比(v/m)为(4-7):1,优选为(5-6):1。
特别是,步骤4)中所述煎煮处理次数优选为1次;步骤4)中所述煎煮处理的温度为100℃;每次煎煮时间30-40min,优选为30min。
其中,步骤5)中所述浓缩煎煮液的体积与原料黄连、黄芩、黄柏、乳香、没药的总质量之比(v/m)为(4-6):1,优选为4:1。
特别是,步骤6)中所述医用酒精选择浓度为75%(v/v)的医用酒精。
尤其是,步骤6)中加入的医用酒精的体积与浓缩煎煮液的体积之比为1:8以上,优选为1:(8-10),进一步优选为1:10。
本发明又一方面提供一种按照上述方法制备而成的治疗带状疱疹的中药组合物。
施用时,先摇匀药液,以使药瓶中部份沉淀在下面的药物能均匀分散于药液中;用棉签沾药液涂于患处;白天每(1±0.2)小时涂药一次;且第三次涂时,用冷开水将前二次的药液迹洗净后再涂;晚上睡眠不必涂药;本药液禁止入眼、禁止入口。
与现有技术相比,本发明中药组合物具有如下优点:
本发明治疗带状疱疹中药组合物为外涂的中药药水,只需外涂纯中药药水,无需用其它任何药物就可达到止痛治愈。
1、本发明所述的治疗带状疱疹组合物针对带状疱疹的发病原因对症治疗。本发明的治疗带状疱疹组合物由多种中药成分复合而成,其中的药物的活性成分,相互协同作用,针对带状疱疹的形成原因进行治疗,以清热、燥湿、解毒、祛瘀、止痛为治疗原则,治疗效果快,作用迅速,疗程短,一般1-2天内就可以止痛,皮肤损伤开始好转,5-6天内所有疹状基本消失,7-10天痊愈且不留后遗症,治愈率高。
2、本发明制备的治疗带状疱疹组合物,采用天然药材合理复配而成,采用本发明的组合物治疗带状疱疹的治疗效果好,愈后不复发,且无后遗症。
3、本发明制备的治疗带状疱疹组合物制备工艺简单,产品质量稳定效果明显,并且使用方便。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
以下通过试验例来进一步阐述本发明所述药物的有益效果,这些试验例包括了本发明药物的药效学试验。
试验例1本发明治疗带状疱疹组合物治疗带状疱疹效果的临床观察(一)一般资料:
本发明治疗带状疱疹组合物(液体制剂)共经过96例观察了解治疗效果,其中儿童患者2例,青年患者57例,中年患者25例,老年患者12例,男性患者58例,女性患者38例。病例均确诊为带状疱疹,且为其他并发症和继发症。
(二)带状疱疹的诊断标准:(中华人民共和国中医药行业标准《中医病证诊断疗效标准》(ZY/T001.1-94))
1、皮损多为绿豆大小的水疤,簇集成群,疤壁紧张,基底色红,常单侧分布,排列成带状。严重者,皮损可表现为出血性,或可见坏疽性损害。皮损发于头面部者,病情往往较重。
2、皮疹出现前,常先有皮肤刺痛或烧灼感,可伴有周身轻度不适,发热。
3、自觉疼痛明显,可有难以忍受的剧痛,或皮疹消退后遗疼痛。
(三)治疗方法
治疗组:施用时,先摇匀药液(实施例1制备药液),以使药瓶中部份沉淀在下面的药物能均匀分散于药液中;用棉签沾药液涂于患处;白天每(1±0.2)小时涂药一次;且第三次涂时,用冷开水将前二次的药液迹洗净后再涂;晚上睡眠不必涂药;本药液禁止入眼、禁止入口。连续用药7-10天。
(四)带状疱疹治疗效果评定标准:(中华人民共和国中医药行业标准《中医病证诊断疗效标准》(ZY/T001.1-94))
1、治愈:皮疹消退,临床体征消失,无疼痛后遗症。
2、好转:皮疹消退约30%,疼痛明显减轻。
3、未愈:皮疹消退不足30%,仍有疼痛。
(五)临床试验结果
实验结果如下:用药1-2天,疼痛终止;3-5天,水泡干瘪,皮疹糜烂浅溃疡结痂,患处肌肤有痒感;7-10天,患处逐渐脱皮治愈。
治疗过程中无不良反应及过敏,后续随访无后遗症。
治疗结果如表1.
结果表明:
1、本发明治疗带状疱疹组合物治疗效果显著,带状疱疹的临床疹状明显消退;治愈率达到100%。
2、本发明治疗带状疱疹组合物作用迅速,见效快,疗程短。
3、对使用本发明产品后患者,跟踪观察6-12个月未出现带状疱疹复发现象,且无后遗症。
本发明的中药组合物使用时间短,为外用药,药物含量低,使用未出现任何毒性反应;而且跟踪观察治愈患者6-12个月,均为发现任何毒性反应,因此,本发明的治疗带状疱疹组合物毒性低,安全范围广。
实施例1
1)按照以下配比称取原料(单位:g)
黄连20、黄芩20、黄柏20、大黄20、马钱子粉20、冰片20、乳香20、没药20、雄黄40
其中,乳香为制乳香;没药选择制没药;
其中:大黄、冰片、雄黄采用粉碎机分别粉碎,过筛,粉碎成粒度小于100目的大黄粉末、冰片粉末、雄黄粉末,备用;
本发明实施例中马钱子粉也可以使用马钱子,如果使用马钱子,则按照如下方法制备成马钱子粉:
将马钱子与若干放入铁锅中,再加入漂洗过的干黄沙置于炉子上不停地翻炒至马钱子壳爆裂,离火,等自然冷却后取出马钱子去壳,将马钱子仁放入粉碎机中粉成粉末,并过筛,取粒度为小于100目的粉末,备用;
2)将黄连、黄芩、黄柏、制乳香、制没药置于煎锅中,加水600ml,浸泡40min,其中黄连、黄芩、黄柏、制乳香、制没药的总质量与水的体积之比为1:6(m/v);
黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比通常为1:5-10,即每1g黄连、黄芩、黄柏、制乳香、制没药的总质量,加水5-10ml;优选为1:6-9;浸泡时间为至少30min,优选为30-60min。
3)加热,100℃煮沸,保持在100℃煮沸的条件下恒温煎煮30min(通常为至少30min,优选为30-40min);然后过滤,得到第一次煎煮液,备用;
第一次煎煮过程中,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:5-10,即每1g黄连、黄芩、黄柏、制乳香、制没药的总质量,加水5-10ml;优选为1:6-9;第一次煎煮时间为至少30min,优选为30-60min,进一步优选为30-40min。
4)向滤渣中加入水500ml,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:5(通常为1:4-7,优选为1:5-6);加热100℃煮沸,保持在100℃煮沸的条件下进行恒温煎煮30min(通常为30-40min);然后过滤,得到第二次煎煮液备用;
第二次煎煮过程中,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:4-7,即每1g黄连、黄芩、黄柏、制乳香、制没药的总质量,加水4-7ml;优选为1:5-6;第二次煎煮时间为至少30min,优选为30-60min,进一步优选为30-40min。
5)将2次煎煮液合并后进行浓缩处理,浓缩至煎煮液体积为400ml,即制得浓缩煎煮液,其中浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为4:1;
浓缩后的浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为(4-6):1,即每1g黄连、黄芩、黄柏、制乳香、制没药的总质量的药材煎煮后的浓缩煎煮液的体积为4-6ml,优选为4:1。
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入75%的医用酒精50ml,搅拌均匀,即得,其中,加入的75%的医用酒精的体积与浓缩煎煮液的体积之比为1:10。
加入的医用酒精的体积与浓缩煎煮液的体积之比通常为1:8以上,优选为1:(8-10),进一步优选为1:10;
制得的中药组合物分装至30ml或50ml的清洁无菌的小药瓶中,置于避光处保存,有效期二年。需要使用时取出药瓶,摇匀后涂于患处,每小时涂药1次。
实施例2
1)按照以下配比称取原料(单位:g)
黄连10、黄芩25、黄柏10、大黄25、马钱子粉20、冰片10、乳香20、没药30、雄黄30
2)将黄连、黄芩、黄柏、制乳香、制没药置于煎锅中,加水850ml,浸泡40min,其中黄连、黄芩、黄柏、制乳香、制没药的总质量与水的体积之比为1:8.95(m/v);
3)加热,100℃煮沸,保持在100℃煮沸的条件下恒温煎煮40min(通常为至少30min,优选为30-40min);然后过滤,得到第一次煎煮液,备用;
4)向滤渣中加入水570ml,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:6(通常为1:4-7,优选为1:5-6);加热100℃煮沸,保持在100℃煮沸的条件下进行恒温煎煮40min(通常为30-40min);然后过滤,得到第二次煎煮液备用;
5)将2次煎煮液合并后进行浓缩处理,浓缩至煎煮液体积为380ml,即制得浓缩煎煮液;其中浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为4:1;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入75%的医用酒精47.5ml,搅拌均匀,即得,其中,加入的75%的医用酒精的体积与浓缩煎煮液的体积之比为1:8。
实施例3
1)按照以下配比称取原料(单位:g)
黄连30、黄芩10、黄柏30、大黄15、马钱子粉10、冰片25、乳香15、没药10、雄黄40
2)将黄连、黄芩、黄柏、制乳香、制没药置于煎锅中,加水480ml,浸泡60min,其中黄连、黄芩、黄柏、制乳香、制没药的总质量与水的体积之比为1:5.05(m/v);
3)加热,100℃煮沸,保持在100℃煮沸的条件下恒温煎煮40min(通常为至少30min,优选为30-40min);然后过滤,得到第一次煎煮液,备用;
4)向滤渣中加入水660ml,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:6.95(通常为1:4-7,优选为1:5-6);加热100℃煮沸,保持在100℃煮沸的条件下进行恒温煎煮30min(通常为30-40min);然后过滤,得到第二次煎煮液备用;
5)将2次煎煮液合并后进行浓缩处理,浓缩至煎煮液体积为570ml,即制得浓缩煎煮液;其中浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为6:1;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入75%的医用酒精60ml,搅拌均匀,即得,其中,加入的75%的医用酒精的体积与浓缩煎煮液的体积之比为1:9.5。
实施例4
1)按照以下配比称取原料(单位:g)
黄连5、黄芩10、黄柏40、大黄30、马钱子粉10、冰片4、乳香12、没药5、雄黄55
2)将黄连、黄芩、黄柏、制乳香、制没药置于煎锅中,加水360ml,浸泡30min,其中黄连、黄芩、黄柏、制乳香、制没药的总质量与水的体积之比为1:5(m/v);
3)加热,100℃煮沸,保持在100℃煮沸的条件下恒温煎煮40min(通常为至少30min,优选为30-40min);然后过滤,得到第一次煎煮液,备用;
4)向滤渣中加入水430ml,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:5.97(通常为1:4-7,优选为1:5-6);加热100℃煮沸,保持在100℃煮沸的条件下进行恒温煎煮40min(通常为30-40min);然后过滤,得到第二次煎煮液备用;
5)将2次煎煮液合并后进行浓缩处理,浓缩至煎煮液体积为290ml,即制得浓缩煎煮液;其中浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为4.03:1;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入75%的医用酒精35ml,搅拌均匀,即得,其中,加入的75%的医用酒精的体积与浓缩煎煮液的体积之比为1:8.3。
实施例5
1)按照以下配比称取原料(单位:g)
黄连40、黄芩50、黄柏4、大黄7、马钱子粉25、冰片30、乳香35、没药40、雄黄25
2)将黄连、黄芩、黄柏、制乳香、制没药置于煎锅中,加水1690ml,浸泡40min,其中黄连、黄芩、黄柏、制乳香、制没药的总质量与水的体积之比为1:10(m/v);
3)加热,100℃煮沸,保持在100℃煮沸的条件下恒温煎煮30min(通常为至少30min,优选为30-40min);然后过滤,得到第一次煎煮液,备用;
4)向滤渣中加入水680ml,黄连、黄芩、黄柏、制乳香、制没药的总质量与加入的水的体积之比为1:4.02(通常为1:4-7,优选为1:5-6);加热100℃煮沸,保持在100℃煮沸的条件下进行恒温煎煮40min(通常为30-40min);然后过滤,得到第二次煎煮液备用;
5)将2次煎煮液合并后进行浓缩处理,浓缩至煎煮液体积为850ml,即制得浓缩煎煮液;其中浓缩煎煮液的体积与黄连、黄芩、黄柏、制乳香、制没药的总质量之比为5.03:1;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入75%的医用酒精85ml,搅拌均匀,即得,其中,加入的75%的医用酒精的体积与浓缩煎煮液的体积之比为1:10。
本发明上述实施例仅是范例性的,并不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改和替换均落入本发明的保护范围内。
Claims (10)
1.一种治疗带状疱疹的中药组合物,其特征是,包括以下原料:黄连、黄芩、黄柏、大黄、马钱子、冰片、乳香、没药、雄黄、医用酒精。
2.如权利要求1所述的组合物,其特征是,所述原料的配比为:
黄连5-40、黄芩10-50、黄柏4-40、大黄7-30、马钱子10-25、冰片4-30、乳香12-35、没药5-40、雄黄25-55,医用酒精适量。
3.如权利要求2所述的组合物,其特征是所述原料的配比选择为:
黄连10-30、黄芩10-25、黄柏10-35、大黄15-25、马钱子10-20、冰片10-25、乳香15-20、没药10-30、雄黄30-40,,医用酒精适量。
4.一种治疗带状疱疹的中药组合物的制备方法,包括下列步骤:
1)按照以下重量份配比备料:
黄连5-40、黄芩10-50、黄柏4-40、大黄7-30、马钱子粉10-25、冰片4-30、乳香12-35、没药5-40、雄黄25-55,
2)将大黄、冰片、雄黄分别采用粉碎机进行粉碎,过筛,粉碎成粒度小于100目的大黄粉末、冰片粉末、雄黄粉末,备用;
3)向黄连、黄芩、黄柏、乳香、没药中加入水,进行浸泡处理;接着加热,煮沸,进行第一次煎煮处理;然后过滤,收集滤液;
4)向滤渣中加入水,加热、煮沸,再进行1-3次煎煮处理;并过滤,收集滤液;
5)合并滤液,并进行浓缩处理,获得浓缩煎煮液;
6)向浓缩煎煮液中加入马钱子粉、大黄粉、冰片粉、雄黄粉;然后加入医用酒精,搅拌均匀,即得。
5.如权利要求4所述的制备方法,其特征是,步骤1)中所述原料的重量份配比为:黄连10-30、黄芩10-25、黄柏10-35、大黄15-25、马钱子10-20、冰片10-25、乳香15-20、没药10-30、雄黄30-40。
6.如权利要求4或5所述的制备方法,其特征是,步骤3)中所述原料黄连、黄芩、黄柏、乳香、没药的总质量之和与加入的水的体积之比为1:(5-10),优选为1:(6-9)。
7.如权利要求4或5所述的制备方法,其特征是,步骤3)中所述浸泡处理时间至少30min,优选为30-60min。
8.如权利要求4或5所述的制备方法,其特征是,步骤4)中所述加入的水体积与原料黄连、黄芩、黄柏、乳香、没药的总质量之比为(4-7):1,优选为(5-6):1。
9.如权利要求4或5所述的制备方法,其特征是,步骤5)中所述浓缩煎煮液的体积与原料黄连、黄芩、黄柏、乳香、没药的总质量之比为(4-6):1,优选为4:1。
10.如权利要求4或5所述的制备方法,其特征是,步骤6)中所述医用酒精选择浓度为75%(v/v)的医用酒精。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011470153.4A CN112402508A (zh) | 2020-12-14 | 2020-12-14 | 一种治疗带状疱疹的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011470153.4A CN112402508A (zh) | 2020-12-14 | 2020-12-14 | 一种治疗带状疱疹的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112402508A true CN112402508A (zh) | 2021-02-26 |
Family
ID=74775082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011470153.4A Pending CN112402508A (zh) | 2020-12-14 | 2020-12-14 | 一种治疗带状疱疹的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112402508A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690657A (zh) * | 2013-12-13 | 2014-04-02 | 石英才 | 一种用于治疗疱疹的高效外用散剂 |
CN104288299A (zh) * | 2014-09-17 | 2015-01-21 | 李厚宽 | 一种治疗带状疱疹的中药外用组合物 |
CN106039023A (zh) * | 2016-07-26 | 2016-10-26 | 王鑫玺 | 一种治疗带状疱疹及其后遗神经痛的药物 |
-
2020
- 2020-12-14 CN CN202011470153.4A patent/CN112402508A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103690657A (zh) * | 2013-12-13 | 2014-04-02 | 石英才 | 一种用于治疗疱疹的高效外用散剂 |
CN104288299A (zh) * | 2014-09-17 | 2015-01-21 | 李厚宽 | 一种治疗带状疱疹的中药外用组合物 |
CN106039023A (zh) * | 2016-07-26 | 2016-10-26 | 王鑫玺 | 一种治疗带状疱疹及其后遗神经痛的药物 |
Non-Patent Citations (4)
Title |
---|
昊晟堂: "【带状疱疹:内服外敷效验方】十一", 《HTTP://WWW.360DOC.COM/CONTENT/19/0228/17/15512571_818177461.SHTML, 2019-02-28》 * |
罗熙财: "《临证散墨》", 31 May 2018, 天津科学技术出版社 * |
蔡建成: "毒剧中药的临床应用与体会", 《中医药学报》 * |
黄秋生,等: "中西医结合治疗带状疱疹疗效观察", 《中国现代药物应用》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104173937A (zh) | 一种疏肝利胆的中药组合物及其应用 | |
CN101569739B (zh) | 一种治疗胆囊炎的中药组合物及其制备方法 | |
CN104491052B (zh) | 治疗风湿及类风湿性关节炎的中药组合物及其制备方法 | |
CN113521232A (zh) | 一种含有白术的中药组合物 | |
CN102078569B (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN101596252B (zh) | 一种治疗带状疱疹的组合物及其制备方法 | |
CN108164524B (zh) | 一种黄藤素及提取方法、黄藤素胶囊及制备方法 | |
CN104274763A (zh) | 治疗外感时毒型复发性口腔溃疡的中药制剂及其制备方法 | |
CN101549016B (zh) | 一种治疗急慢性咽炎的中药组合物及其制备方法 | |
CN103285230B (zh) | 用于治疗咽炎的药物组合物及其制备方法 | |
CN103055065B (zh) | 治疗鱼类肠炎的中药组合物及其制备方法 | |
CN101024026A (zh) | 一种治疗腮腺炎的药物 | |
CN104623376B (zh) | 用于治疗三叉神经痛的药物 | |
CN107007784B (zh) | 用于逆转Aβ淀粉样蛋白损伤神经细胞的中药组合物及其制备方法与应用 | |
CN114377095A (zh) | 一种砂仁-檀香挥发油提取方法、治疗胃炎的胶囊及其制备方法 | |
CN112402508A (zh) | 一种治疗带状疱疹的中药组合物及其制备方法 | |
CN110384785B (zh) | 一种用于治疗病毒性感冒的外用中药药液及其制备方法 | |
CN113181318A (zh) | 一种治疗痔疮的中药药膏及其制备方法 | |
CN106421283A (zh) | 一种治疗皮肤疾病的中药药膏 | |
CN110772623A (zh) | 治疗前列腺的中药 | |
CN111658748A (zh) | 用于治疗痛经的组合物、口服制剂及应用 | |
CN112439016B (zh) | 一种治疗急性软组织损伤的中药组合物、制备方法及应用 | |
CN114470063B (zh) | 一种用于治疗软组织损伤的复方中药片 | |
CN114099571A (zh) | 一种治疗关节痛的组合物及其制备方法 | |
CN103784706A (zh) | 一种治疗马属动物肠臌气的药物组合 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |